BCAL Diagnostics (ASX:BDX) FCF Yield % : -15.64 (As of May. 17, 2024)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, BCAL Diagnostics's Trailing 12-Month Free Cash Flow is A$-4.34 Mil, and Market Cap is A$27.75 Mil. Therefore, BCAL Diagnostics's FCF Yield % for today is -15.64%.

The historical rank and industry rank for BCAL Diagnostics's FCF Yield % or its related term are showing as below:

ASX:BDX' s FCF Yield % Range Over the Past 10 Years
Min: -28.68 Med: 0 Max: 0
Current: -15.64

ASX:BDX's FCF Yield % is ranked worse than
68.53% of 232 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.42 vs ASX:BDX: -15.64

BCAL Diagnostics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

BCAL Diagnostics FCF Yield % Historical Data

The historical data trend for BCAL Diagnostics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics FCF Yield % Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

FCF Yield %

-43.66

-40.69

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial			-16.36	-70.46	-43.49	-44.77	-8.07

Competitive Comparison of BCAL Diagnostics's FCF Yield %

For the Diagnostics & Research subindustry, BCAL Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's FCF Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's FCF Yield % falls into.

BCAL Diagnostics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

BCAL Diagnostics's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-6.048	/	14.86205
	=	-40.69%

BCAL Diagnostics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.015	*	2	/	25.1639
	=	-8.07%

BCAL Diagnostics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

BCAL Diagnostics FCF Yield % Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.